Conferences - Results from #11180

Viewing 11181-11200 of 11869 articles

ASCO 2013 - Poster: Pain analyses from the phase III randomized ALSYMPCA study with radium-223 dichloride in castration-resistant prostate cancer (CRPC) patients with bone metastases

ASCO 2013 - Poster: Hematologic safety of radium-223 dichloride in castration-resistant prostate cancer (CRPC) patients with bone metastases from the phase III ALSYMPCA trial

ASCO 2013 - Poster: CA184-095: A randomized, double-blind, phase 3 trial to compare the efficacy of ipilimumab vs placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naïve castration-resistant prostate cancer

ASCO 2013 - Poster: Preliminary safety, product parameters, and immune response assessments from a phase II, randomized, open-label trial of DN24-02, an autologous cellular immunotherapy, in patients with surgically resected HER+ urothelial cancer at high

ASCO 2013 - Poster: Preliminary HER2 expression data from NeuACT, the phase II randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer at high risk for recurrence

ASCO 2013 - Poster: A randomized, phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate plus prednisone in metastatic castrate-resistant prostate cancer (mCRPC)

ASCO 2013 - Poster: Randomized phase II trial evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in patients with biochemically recurrent prostate cancer (BRPC): Immune results

ASCO 2013 - Poster: The impact of reducing the frequency of prostate specific antigen (PSA) testing among men on active surveillance for prostate cancer

ASCO 2013 - Poster: The impact of reducing the frequency of prostate specific antigen (PSA) testing among men on active surveillance for prostate cancer

ASCO 2013 - Podcast: The impact of reducing the frequency of prostate specific antigen (PSA) testing among men on active surveillance for prostate cancer

ASCO 2013 - Podcast: The impact of reducing the frequency of prostate specific antigen (PSA) testing among men on active surveillance for prostate cancer

ASCO 2013 - Poster: Correlation between baseline variables and survival in the radium-223 dichloride phase III ALSYMPCA trial with attention to total ALP changes

ASCO 2013 - Podcast: Correlation between baseline variables and survival in the radium-223 dichloride phase III ALSYMPCA trial with attention to total ALP changes

ASCO 2013 - Slide Presentation: CRPC: The place of novel agents focused on the androgen axis

ASCO 2013 - Podcast: CRPC: The place of novel agents focused on the androgen axis

APIC 2013 - Podcast: Effectiveness of a silver-alloy and hydrogel coated urinary catheter on symptomatic catheter-associated urinary tract infections

ASCO 2013 - Poster: Evolving patterns of metastatic disease in castration-resistant prostate cancer (CRPC) reported in clinical trials from 1990 to 2011

ASCO 2013 - Poster: Novel predictive markers of PSA response to abiraterone acetate in men with metastatic castration-resistant prostate cancer (mCRPC)

ASCO 2013 - Podcast: Novel predictive markers of PSA response to abiraterone acetate in men with metastatic castration-resistant prostate cancer (mCRPC)

ASCO 2013 - Poster: Efficacy and safety of radium-223 dichloride in castration-resistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel in the phase 3 ALSYMPCA trial

555
556
557
558
559
560
561
562
563
564